{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:09:54Z","timestamp":1774588194183,"version":"3.50.1"},"reference-count":127,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2K12CA226330-06"],"award-info":[{"award-number":["2K12CA226330-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA294824-01"],"award-info":[{"award-number":["R01CA294824-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NCT06040099"],"award-info":[{"award-number":["NCT06040099"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.soc.2025.10.008","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T21:07:23Z","timestamp":1768424843000},"page":"347-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy"],"prefix":"10.1016","volume":"35","author":[{"given":"Cindy M.","family":"Pabon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyush","family":"Kumar-Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin O.","family":"Spieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Tuerff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jashodeep","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Hosein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2018.11.071","article-title":"DNA mismatch repair deficiency and immune checkpoint inhibitors in gastrointestinal cancers","volume":"156","author":"Ruiz-Banobre","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.soc.2025.10.008_bib3","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","article-title":"Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review","volume":"9","author":"Emiloju","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soc.2025.10.008_bib4","unstructured":"Servier Medical Art, https:\/\/smart.servier.com, licensed under CC BY 4.0. Available at: https:\/\/creativecommons.org\/licenses\/by\/4.0\/."},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib5","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.21037\/jgo-23-85","article-title":"Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review","volume":"14","author":"Tan","year":"2023","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051031","article-title":"The interplay between DNA repair and the immune microenvironment in pancreatic cancer","volume":"13","author":"Ciner","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.soc.2025.10.008_bib7","article-title":"Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000942","article-title":"Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma","volume":"5","author":"Seeber","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.soc.2025.10.008_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.860767","article-title":"Intra-tumoral CD8+ T-Cell infiltration and PD-L1 positivity in homologous recombination deficient pancreatic ductal adenocarcinoma","volume":"12","author":"Golesworthy","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","article-title":"Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants","volume":"8","author":"Terrero","year":"2022","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.10.008_bib11","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-19-2803","article-title":"A four-chemokine signature is associated with a T-cell-Inflamed phenotype in primary and metastatic pancreatic cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.10.008_bib12","doi-asserted-by":"crossref","unstructured":"Ogobuiro I, Bianchi A, Caeiro L, et al. Chronic platinum exposure induces intrinsic type 1 interferon\/STING pathway activation in homologous recombination-deficient pancreatic cancer to drive sensitivity to checkpoint immunotherapy [abstract C064]. In: Proceedings of the American Association for Cancer Research Special Conference: Pancreatic Cancer; September 27-30, 2023; Boston (MA).","DOI":"10.1158\/1538-7445.PANCA2023-C064"},{"issue":"16","key":"10.1016\/j.soc.2025.10.008_bib13","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2025.43.16_suppl.4176","article-title":"Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD)","volume":"43","author":"Oh","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.2025.43.4_suppl.715","article-title":"Nivolumab plus ipilimumab (N + I) in patients (pts) with pancreatic cancer (PC) with BRCA1\/2 mutation (mut): results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"43","author":"Hosein","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.soc.2025.10.008_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.soc.2025.10.008_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2023.02.016","article-title":"Pembrolizumab for previously treated, microsatellite instability-high\/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164","volume":"186","author":"Le","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.soc.2025.10.008_bib18","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ijc.25106","article-title":"Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes","volume":"127","author":"Michel","year":"2010","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000050630","article-title":"Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours","volume":"22","author":"Bustin","year":"2001","journal-title":"Tumour Biol"},{"key":"10.1016\/j.soc.2025.10.008_bib21","doi-asserted-by":"crossref","unstructured":"Middleton G, Liu EW, Savage J, et al. Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): results of the ANICCA-class II trial. Presented at: ESMO; Barcelona, Spain 9-13th September, 2022.","DOI":"10.1016\/j.annonc.2022.07.564"},{"key":"10.1016\/j.soc.2025.10.008_bib22","article-title":"Nivolumab plus ipilimumab in patients with solid tumors with ATM mutations: results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"7","author":"Rohatgi","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.soc.2025.10.008_bib25","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2025.10.008_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101917","article-title":"Regorafenib plus nivolumab in patients with mismatch repair-proficient\/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study","volume":"58","author":"Fakih","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib27","article-title":"Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results","volume":"4","author":"Saeed","year":"2023","journal-title":"Cell Rep Med"},{"issue":"22","key":"10.1016\/j.soc.2025.10.008_bib28","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1200\/JCO.23.02728","article-title":"Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study","volume":"42","author":"Antoniotti","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.10.008_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008409","article-title":"Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial","volume":"12","author":"Lenz","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.soc.2025.10.008_bib30","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1158\/2159-8290.CD-24-0190","article-title":"Botensilimab, an Fc-Enhanced Anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.soc.2025.10.008_bib32","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.soc.2025.10.008_bib33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"230","key":"10.1016\/j.soc.2025.10.008_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.soc.2025.10.008_bib35","unstructured":"Marwan FNHS, Schlechter BL, Andre T, et al. Manuel Hidalgo preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM). Presented at: GI ASCO; January 27, 2025 2025; San Francisco, CA, USA."},{"key":"10.1016\/j.soc.2025.10.008_bib36","series-title":"A phase 1 trial of folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) in microsatellite stable metastatic colorectal cancer","author":"Marwan Fakih","year":"2025"},{"key":"10.1016\/j.soc.2025.10.008_bib37","doi-asserted-by":"crossref","unstructured":"Ghelardi F, Ambrosini M, Raimondi A, et al. Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO. Presented at: GI ASCO; 2025; San Francisco, CA, USA.","DOI":"10.1200\/JCO.2025.43.4_suppl.158"},{"key":"10.1016\/j.soc.2025.10.008_bib38","doi-asserted-by":"crossref","unstructured":"Hissong E, Jafari MD, Khan S, et al. Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update. Presented at: GI ASCO; January 27, 2025 2025; San Francisco, CA, USA.","DOI":"10.1200\/JCO.2025.43.4_suppl.207"},{"issue":"7","key":"10.1016\/j.soc.2025.10.008_bib39","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","article-title":"Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer","volume":"35","author":"Ambrosini","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.soc.2025.10.008_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002797","article-title":"Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors","volume":"9","author":"Hwang","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13046-022-02422-1","article-title":"POLE\/POLD1 mutation and tumor immunotherapy","volume":"41","author":"Ma","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.soc.2025.10.008_bib42","unstructured":"Benson AB, Venook AP, Adam M, et al. National Comprehensive Cancer Network. Colon Cancer (Version 3.2025). 2025."},{"issue":"12","key":"10.1016\/j.soc.2025.10.008_bib43","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41436-020-0922-2","article-title":"Role of POLE and POLD1 in familial cancer","volume":"22","author":"Mur","year":"2020","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"7517","key":"10.1016\/j.soc.2025.10.008_bib45","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1938381","article-title":"The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in epstein-barr virus-associated gastric cancer","volume":"10","author":"Wei","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-81764-6","article-title":"Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.soc.2025.10.008_bib48","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnci\/djx213","article-title":"Immune activation and benefit from avelumab in EBV-positive gastric cancer","volume":"110","author":"Panda","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"10.1016\/j.soc.2025.10.008_bib49","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.soc.2025.10.008_bib50","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jss.2024.01.043","article-title":"Immune landscape of Epstein-Barr virus-associated gastric cancer: analysis from a Western academic institution","volume":"296","author":"Yee","year":"2024","journal-title":"J Surg Res"},{"issue":"9","key":"10.1016\/j.soc.2025.10.008_bib51","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/CJI.0000000000000316","article-title":"Positive status of Epstein-Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study","volume":"43","author":"Xie","year":"2020","journal-title":"J Immunother"},{"key":"10.1016\/j.soc.2025.10.008_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1003859","article-title":"Case report: long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer","volume":"13","author":"Pan","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.soc.2025.10.008_bib54","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib55","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41698-021-00200-4","article-title":"The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response","volume":"5","author":"Wang","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"15","key":"10.1016\/j.soc.2025.10.008_bib56","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","article-title":"Epithelial-to-Mesenchymal transition contributes to immunosuppression in breast carcinomas","volume":"77","author":"Dongre","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.soc.2025.10.008_bib58","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-20-4459","article-title":"Tumor immune microenvironment during epithelial-mesenchymal transition","volume":"27","author":"Taki","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.soc.2025.10.008_bib59","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1136\/gutjnl-2022-329134","article-title":"Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-gamma signalling","volume":"72","author":"Cao","year":"2023","journal-title":"Gut"},{"issue":"13","key":"10.1016\/j.soc.2025.10.008_bib60","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-21-4370","article-title":"Epithelial-Mesenchymal plasticity in tumor immune evasion","volume":"82","author":"Mullins","year":"2022","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.soc.2025.10.008_bib61","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1878-0261.12093","article-title":"New insights into the role of EMT in tumor immune escape","volume":"11","author":"Terry","year":"2017","journal-title":"Mol Oncol"},{"issue":"9","key":"10.1016\/j.soc.2025.10.008_bib62","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1158\/1078-0432.CCR-10-2203","article-title":"Molecular classification of gastric cancer: a new paradigm","volume":"17","author":"Shah","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib63","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1038\/s41598-018-21061-1","article-title":"Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)","volume":"8","author":"Chae","year":"2018","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.soc.2025.10.008_bib64","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.soc.2025.10.008_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117043","article-title":"Targeting oncogenic signal pathway to improve cancer immunotherapy: insights and perspectives","volume":"239","author":"Yang","year":"2025","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"13","key":"10.1016\/j.soc.2025.10.008_bib67","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"305","key":"10.1016\/j.soc.2025.10.008_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation; radiobiology or medicine?","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"10.1016\/j.soc.2025.10.008_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.radonc.2021.06.037","article-title":"High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial","volume":"162","author":"Patel","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib70","first-page":"71","article-title":"The role of biologically effective dose (BED) in clinical oncology","volume":"13","author":"Jones","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.soc.2025.10.008_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171559","article-title":"A meta-analysis of the abscopal effect in preclinical models: is the biologically effective dose a relevant physical trigger?","volume":"12","author":"Marconi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.soc.2025.10.008_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2021.12.018","article-title":"An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer","volume":"167","author":"Sheikh","year":"2022","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","article-title":"Stereotactic body radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch(R) patient registry","volume":"13","author":"Mahadevan","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.soc.2025.10.008_bib75","article-title":"Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases","volume":"46","author":"Ugurluer","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.soc.2025.10.008_bib76","first-page":"45","article-title":"High versus low dose stereotactic body radiation therapy for hepatic metastases","volume":"20","author":"Kok","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib77","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib78","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijrobp.2009.08.020","article-title":"Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies","volume":"78","author":"Goodman","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.soc.2025.10.008_bib79","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1001\/jamaoncol.2021.2939","article-title":"Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans Tasman radiation oncology group 13.01 phase 2 randomized clinical trial","volume":"7","author":"Siva","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.10.008_bib80","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijrobp.2022.02.038","article-title":"Single-fraction celiac plexus radiosurgery: a preliminary proof-of-concept phase 2 clinical trial","volume":"113","author":"Hammer","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib81","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2010.05.006","article-title":"Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer","volume":"81","author":"Schellenberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib82","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib83","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/2016.9.FOCUS16369","article-title":"The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery","volume":"42","author":"Yamada","year":"2017","journal-title":"Neurosurg Focus"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib84","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1227\/NEU.0000000000000083","article-title":"Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum","volume":"73","author":"Yamada","year":"2013","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib85","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1172\/JCI97631","article-title":"Single-dose radiotherapy disables tumor cell homologous recombination via ischemia\/reperfusion injury","volume":"129","author":"Bodo","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.soc.2025.10.008_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fcell.2020.00041","article-title":"Molecular mechanisms of radiation-induced cancer cell death: a primer","volume":"8","author":"Sia","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.soc.2025.10.008_bib87","article-title":"The cGAS\/STING pathway: a novel target for cancer therapy","volume":"12","author":"Gan","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.soc.2025.10.008_bib88","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/cncr.20270","article-title":"The role of fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy","volume":"100","author":"Kim","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2025.10.008_bib89","doi-asserted-by":"crossref","DOI":"10.1177\/1758834017742575","article-title":"Radiation effects on antitumor immune responses: current perspectives and challenges","volume":"10","author":"Walle","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/153303460200100207","article-title":"The impact of TNF-alpha induction on therapeutic efficacy following high dose spatially fractionated (GRID) radiation","volume":"1","author":"Sathishkumar","year":"2002","journal-title":"Technol Cancer Res Treat"},{"issue":"24","key":"10.1016\/j.soc.2025.10.008_bib91","doi-asserted-by":"crossref","first-page":"11811","DOI":"10.1158\/0008-5472.CAN-07-0722","article-title":"Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma","volume":"67","author":"Shareef","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.soc.2025.10.008_bib92","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4161\/cbt.4.9.1915","article-title":"Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis","volume":"4","author":"Sathishkumar","year":"2005","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib93","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/157436207780619509","article-title":"Potential utilization of bystander\/abscopal-mediated signal transduction events in the treatment of solid tumors","volume":"2","author":"Matthew","year":"2007","journal-title":"Curr Signal Transduct Ther"},{"issue":"6576","key":"10.1016\/j.soc.2025.10.008_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib95","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.soc.2025.10.008_bib96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib98","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.ijrobp.2009.10.014","article-title":"Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer","volume":"76","author":"Battaglia","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.soc.2025.10.008_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179401","article-title":"Immune checkpoint therapy: tumor draining lymph nodes in the spotlights","volume":"22","author":"Fransen","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13014-019-1227-y","article-title":"Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects","volume":"14","author":"Tubin","year":"2019","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010050","article-title":"Shifting the immune-suppressive to predominant immune-stimulatory radiation effects by SBRT-PArtial tumor irradiation targeting HYpoxic segment (SBRT-PATHY)","volume":"13","author":"Tubin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.soc.2025.10.008_bib102","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/0284186X.2017.1346385","article-title":"Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients","volume":"56","author":"Tubin","year":"2017","journal-title":"Acta Oncol"},{"issue":"25","key":"10.1016\/j.soc.2025.10.008_bib103","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-Term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.soc.2025.10.008_bib104","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): a multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.soc.2025.10.008_bib106","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41591-020-01190-9","article-title":"Liver metastases inhibit immunotherapy efficacy","volume":"27","author":"Lindblad","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.soc.2025.10.008_bib107","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib108","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.soc.2025.10.008_bib109","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.soc.2025.10.008_bib110","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.10.008_bib111","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.soc.2025.10.008_bib112","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"issue":"27","key":"10.1016\/j.soc.2025.10.008_bib113","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1200\/JCO.21.02511","article-title":"Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC)","volume":"40","author":"Chen","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib114","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","article-title":"Use of multi-site radiation therapy for systemic disease control","volume":"109","author":"Patel","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.10.008_bib116","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation therapy and immunotherapy: what is the optimal timing or sequencing?","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.soc.2025.10.008_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092572","article-title":"Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model","volume":"9","author":"Yoshimoto","year":"2014","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.soc.2025.10.008_bib118","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.soc.2025.10.008_bib119","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrclinonc.2016.30","article-title":"Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?","volume":"13","author":"Bernstein","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.10.008_bib120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1016709","article-title":"The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade","volume":"4","author":"Dovedi","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib121","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"Suppl 7","key":"10.1016\/j.soc.2025.10.008_bib122","doi-asserted-by":"crossref","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib123","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2022.07.076","article-title":"Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer","volume":"163","author":"Datta","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.soc.2025.10.008_bib124","article-title":"A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma","volume":"42","author":"Hosein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.10.008_bib125","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2767-9764.CRC-24-0172","article-title":"Reshaping the tumor microenvironment of KRASG12D pancreatic ductal adenocarcinoma with combined SOS1 and MEK inhibition for improved immunotherapy response","volume":"4","author":"Norgard","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.soc.2025.10.008_bib126","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.soc.2025.10.008_bib127","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","article-title":"T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of pancreatic ductal adenocarcinoma","volume":"15","author":"Orlen","year":"2025","journal-title":"Cancer Discov"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:02:52Z","timestamp":1774580572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1055320725000924"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.008","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}